In early November, Pfizer and its German partner, BioNtech, released results of their ongoing trial for a COVID-19 vaccine, showing very positive early results of 90% efficacy rates. Shortly after, Moderna followed suit with similarly positive results from their COVID vaccine trial. In the midst of a second wave of increasing case counts and the communal weariness from ongoing (and increasing) restrictions and lockdowns, the good news couldn’t have come soon enough. Investors around the globe were quick to hitch their wagons to the idea of a vaccine-enabled return to gatherings, events, traditional business functions and economic activity.
To continue reading please click HERE
We would like to take this opportunity to express thanks and gratitude to our associates,…
Introduction Global equity markets finished largely unchanged over the month of November. Enthusiasm for artificial…
October was a month of mixed signals. While equities climbed and AI leaders like NVIDIA…
Markets gained ground in September, lifted by rate cuts and easing inflation. Canadian and U.S.…
Investor sentiment improved in August, driven by hopes of rate cuts and extended trade truces.…
Trade tensions and cautious monetary policy continue to shape the global economic landscape. The U.S.…